GLENN JOHN

CFO Glenn John sells 15,000 shares (63.9% of holdings) at $97.29 avg; stock up 35.0% in 90 days.

Glenn John, CFO of IRADIMED CORP, executed 2 separate sales totaling 15,000 shares for $1,459,341.56 on 2025-12-11, reducing his holdings from 23,460 to 8,460 shares—a 63.9% reduction. The transactions occurred at a blended average price of $97.29, near the 52-week high of $97.38 and 1.2% below it. The company's stock has appreciated 35.0% over the prior 90 days and 11.3% over 30 days, reflecting strong recent momentum; fundamentals show annual revenue growth of 11.7%, net income of $5,576,652.00, and a P/E of 57.62. This substantial reduction in CEO equity stake during a period of elevated valuation and strong price appreciation merits monitoring for context on management's capital allocation priorities and conviction level at current valuations.

CFO Glenn John sold 10,651 shares (81.0% of holdings) for $900,161.81 at $84.51 on 2025-11-10

CFO Glenn John sold 10,651 shares of IRMD at $84.51, reducing his holdings by 81.0% to just 2,500 shares remaining. The sale occurred when the stock was trading -0.4% from its 52-week high of $86.74, following a 19.4% gain over the prior 30 days and 23.2% over 90 days. The company is posting strong fundamentals with Revenue $21,202,064.00 and Net income $5,576,652.00 in the latest quarter, backed by annual revenue growth of 11.7%, though the P/E of 51.75 reflects a premium valuation. The substantial reduction in personal holdings by the CFO during a near-peak price environment and elevated momentum period merits investor scrutiny into whether this represents a structural shift in leadership's stake or is tied to specific personal circumstances.